Ascentage Pharma Group International (AAPG) Total Non-Current Liabilities (2023 - 2024)
Historic Total Non-Current Liabilities for Ascentage Pharma Group International (AAPG) over the last 3 years, with Q2 2025 value amounting to -$1.1 million.
- Ascentage Pharma Group International's Total Non-Current Liabilities changed N/A to -$1.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.1 million, marking a year-over-year change of. This contributed to the annual value of $161.3 million for FY2024, which is 2380.4% down from last year.
- Per Ascentage Pharma Group International's latest filing, its Total Non-Current Liabilities stood at -$1.1 million for Q2 2025.
- In the past 5 years, Ascentage Pharma Group International's Total Non-Current Liabilities ranged from a high of $207.7 million in Q4 2023 and a low of -$1.1 million during Q2 2025
- Its 3-year average for Total Non-Current Liabilities is $123.5 million, with a median of $163.9 million in 2024.
- Data for Ascentage Pharma Group International's Total Non-Current Liabilities shows a peak YoY increase of 2111.33% (in 2024) and a maximum YoY decrease of 2111.33% (in 2024) over the last 5 years.
- Over the past 3 years, Ascentage Pharma Group International's Total Non-Current Liabilities (Quarter) stood at $207.7 million in 2023, then decreased by 21.11% to $163.9 million in 2024, then plummeted by 100.65% to -$1.1 million in 2025.
- Its Total Non-Current Liabilities stands at -$1.1 million for Q2 2025, versus $163.9 million for Q4 2024 and $207.7 million for Q4 2023.